摘要
目的探讨玻璃体腔注射雷珠单抗治疗脉络膜新生血管的临床效果。方法随机选取该院于2012年2月—2015年1月收治的脉络膜新生血管患者80例,根据随机抽签原则分为治疗组与对照组各40例,所有患者都给予玻璃体腔注射药物治疗,治疗组与对照组分别于角膜缘后4 mm左右垂直进针,缓慢推注雷珠单抗0.05 m L(1 mg/0.1 m L)和贝伐单抗0.05 m L(1mg/0.1 m L)。结果术后1个月进行调查,治疗组的视力有效率为97.5%,对照组为87.5%,治疗组的视力有效率明显高于对照组(P<0.05)。术后1个月两组的黄斑视网膜厚度与术前对比差异有统计学意义(P<0.05),同时治疗组术后1个月的黄斑视网膜厚度明显少于对照组(P<0.05)。结论玻璃体腔注射雷珠单抗治疗脉络膜新生血管能有效降低黄斑视网膜厚度,从而提高术后视力。
Objectiveb To investigate the clinical results of treatment of choroidal neovascularization with vitreous injection of monoclonal antibody. Methods 80 patients from 2012 February to 2015 January with choroidal neovascularization in accordance with the principle of random draw into the treatment group and the control group,and each group has 40 patients, all patients were given intravitreal injection of medication, the treatment group and the control group in the limbus, about 4mm vertical needle slowly bolus injection of Ranibizumab 0.05 m L(1mg/0.1 m L) and bevacizumab 0.05 m L(1mg/0.1 m L). Results After a month investigation, vision therapy group effective rate was 97.5% in the control group, 87.5% had vision therapy group was significantly higher(P<0.05). Thickness and preoperative contrast macular one month after the two groups were significantly different(P <0.05), while the treatment group after one month of macular retinal thickness was significantly less than the control group(P <0.05). Conclusion Intravitreal injection of ranibizumab treatment of choroidal neovascularization can reduce macular thickness, thereby improving visual acuity.
出处
《中外医疗》
2015年第23期104-105,共2页
China & Foreign Medical Treatment
